Poster for European Congress of Clinical Microbiology and Infectious Diseases 2023
April 15, 2023
The SAIVE Trial, Post-Exposure use of ivermectin in Covid-19 prevention: Efficacy and Safety Results
Ivermectin (IVM) is a well-known drug currently used to treat several parasitic diseases. It has a proven safety profile over many decades of exposure. It is one of the several drugs explored for its potential therapeutic and preventive role against SARS-CoV-2 infection as previous studies had reported its antiviral effects on both RNA and DNA viruses1,2. Caly et al. demonstrated that a single dose of IVM could control the in vitro replication of SARS-CoV-23. Several mechanisms of action have been suggested for its effect on SARS-CoV-24. Those mechanisms could lead to an efficient SARS-CoV-2 prevention, independently of virus mutations5. Post-exposure prophylaxis (PEP) is a method of preventing SARS-CoV-2 infection after a known exposure to the virus that may limit the spread of infection.